ClinicalTrials.gg
RecruitingNCT06671587China Soli-CGMUpdated Mar 17, 2026

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

A Phase 4 interventional study of iGlarLixi (insulin glargine/lixisenatide) and Gla-100 (insulin glargine) in Type 2 Diabetes (T2D), sponsored by Sanofi. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
678
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Planned enrollment
28th of 175
678 · median 253
Started
2024
with 3 others
Phase 4
103 of 176
2 open now
Registered
173rd of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 28th largest by planned enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2024, is one of 103 in phase 4, and was the 173rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR from CGM device in Chinese insulin naïve patients with T2D inadequately controlled with OADs. At the end of the screening period, eligible participants will be randomized to one of two treatment groups (iGlarLixi or Gla-100 group). The randomization (1:1) will be stratified by values of HbA1c at screening (\<8.0%, ≥8.0%), and background treatment (metformin only, metformin+SGLT-2i).

Study details include:

  • The study duration per participant will be approximately up to 24 weeks.
  • The treatment duration will be up to 20 weeks.
  • The number of visits will be 14 visits including 9 times of on-site visits and 5 times of phone call visits in total during screening and treatment periods. On-site every 1 week will be from screening till randomization (Week 0), then on site or phone call visit every 2 weeks till Week 12, then every 3 weeks till Week 18, and the End of Treatment visit will be conducted at Week 20. There will be a safety follow-up by a phone call visit (End of Study) in 3 days (-1/+3 days) after the last dose of the treatment.
  • Health measurement/Observation: change in TIR as the primary endpoint
  • Intervention name: iGlarLixi and Gla-100
  • Participant gender: male and female
  • Participant age range: adults at least 18 years of age
  • Condition/disease: type 2 diabetes
  • Study hypothesis: compared to Gla-100, iGlarLixi will demonstrate a superiority therapeutic effect on glycemic control assessed by change in TIR measured with CGM from baseline to Week 20 in the study participants.
03

Conditions studied

  • Type 2 Diabetes (T2D)

Keywords

  • Glucagon-like peptide-1 receptor agonist (GLP-1 RA)
  • FRC (fixed ration combination)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are diagnosed as T2D of at least 1 year before screening visit
  • Participants who are treated at least 3 months prior to screening visit with a stable dose of metformin alone or in combination with a second OAD
  • Inadequate control
  • (BMI) within the range 20-40 kg/m2 (inclusive)
  • Is willing and able to wear the CGM device continuously
  • Is willing to discontinue daily (oral) SU, glinide, alpha-GI, and DPP-4i
  • Not using another CGM device during the study

Exclusion criteria

Exclusion Criteria:

  • Participants with severe renal dysfunction
  • Participants with short
  • Participants with conditions/concomitant diseases making them non evaluable for the efficacy endpoints
  • Participants with conditions/concomitant diseases precluding their safe participation in this study
  • An episode of severe hypoglycemia requiring the assistance of a third party within 3 months before screening visit
  • History of pancreatitis or severe gastrointestinal disorders
  • Participants who have any history of severe multiple allergies or an allergy resulting in anaphylaxis, or / to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Previous treatment with insulin
  • Use of any glucose-lowering agents other than metformin alone or in combination with a second OAD (can be a SU, a glinide, an alpha-GI, a DPP-4i, or a SGLT-2i)
  • Use of systemic
  • Use of weight loss drugs
  • History of discontinuation of a previous treatment with GLP-1 RA for safety/tolerability reasons or lack of efficacy
  • Laboratory findings at the screening visit
  • Participants have any current or previous skin conditions
  • Participants unwilling or unable to do blood glucose monitoring using the Sponsor-provided blood glucometer at home

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
678 participants (estimated)

Study arms

  • Experimental
    iGlarLixi (insulin glargine/lixisenatide)

    Participants will receive iGlarLixi once daily for 20 weeks. iGlarLixi is to be initiated with the starting daily dose of 5-10 dose steps on Visit 4 (Day 1) and will be titrated according to fasting SMBG to achieve glycemic target of ≥80 and ≤110 mg/dL.

    Drug: iGlarLixi (insulin glargine/lixisenatide)

  • Active comparator
    Gla-100 (insulin glargine)

    Participants will receive Gla-100 once daily for 20 weeks. Gla-100 is to be initiated with the starting daily dose of 5-10 U on Visit 4 (Day 1) and will be titrated according to fasting SMBG to achieve and maintain same glycemic target of ≥80 and ≤110 mg/dL.

    Drug: Gla-100 (insulin glargine)

Interventions

  • DrugiGlarLixi (insulin glargine/lixisenatide)

    Drug pages: Insulin Glargine · Lixisenatide

    iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector. There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day: \- iGlarLixi must not be mixed with other insulins nor diluted.

    Also known as: SOLIQUA®

  • Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.

    Also known as: LANTUS®

06

What researchers measure

Primary outcomes

  1. Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]

    Superiority of mean change in the percentage of TIR \[3.9-10.0 mmol/L (70-180 mg/dL)\] from baseline to Week 20 of iGlarLixi vs Gla-100

    Time frame: from baseline to Week 20

Secondary outcomes

  1. 2a Proportion (%) of participants achieving TIR target as >70%

    Time frame: Week 20

  2. 2b Change (%) in TAR >10.0 mmol/L (>180 mg/dL)

    Time frame: from baseline to Week 20

  3. 2c Change (mg/dL) in mean daily glucose

    Time frame: from baseline to Week 20

  4. 2d Proportion (%) of participants achieving composite target of TIR as >70% [3.9-10.0 mmol/L (70-180 mg/dL)] with TAR as <25% [>10.0 mmol/L (>180 mg/dL)] with TBR as <4% [<3.9 mmol/L (<70 m)/dL)]

    Time frame: Week 20

  5. Change (%) in coefficient of variation (CV)

    Time frame: from baseline to Week 20

  6. Change (%) in the percentage of time in tight range (TITR) [3.9-7.8 mmol/L (70-140 mg/dL)]

    Time frame: from baseline to Week 20

  7. Proportion (%) of participants achieving TITR [3.9-7.8 mmol/L (70-140 mg/dL)] >50%

    Time frame: Week 20

  8. Proportion (%) of participants achieving ≥5% TIR improvement

    Time frame: from baseline to Week 20

  9. Proportion (%) of participants achieving ≥10% TIR improvement

    Time frame: from baseline to Week 20

  10. Change (%) in TAR >13.9 mmol/L (>250 mg/dL)

    Time frame: from baseline to Week 20

  11. Change (%) in time below range (TBR)

    * \<3.9 mmol/L (\<70 mg/dL), including \<3.0 mmol/L (\<54 mg/dL) * \<3.0 mmol/L (\<54 mg/dL) * \<3.9 mmol/L (\<70 mg/dL), including \<3.0 mmol/L (\<54 mg/dL) in nocturnal (00:00 h-05:59 h) time * \<3.0 mmol/L (\<54 mg/dL) in nocturnal (00:00 h-05:59 h) time

    Time frame: from baseline to Week 20

  12. Change in mean glucose standard deviation (SD)

    Time frame: from baseline to Week 20

  13. Change (%) in glucose management indicator (GMI)

    Time frame: from baseline to Week 20

  14. Proportion (%) of participants achieving CV <36%

    Time frame: Week 20

  15. Proportion (%) of participants achieving CV <32%

    Time frame: Week 20

  16. Change (%) in HbA1c

    Time frame: from baseline to Week 12 and Week 20

  17. Proportion (%) of participants achieving HbA1c <7%

    Time frame: Week 12 and Week 20

  18. Proportion (%) of participants achieving HbA1c <7% without documented hypoglycemia

    documented hypoglycemia (defined as ADA Level 1, 2 or 3)

    Time frame: Week 20

  19. Proportion (%) of participants achieving HbA1c <7% without body weight gain

    body weight gain (≥5% compared to baseline)

    Time frame: Week 20

  20. Proportion (%) of participants achieving HbA1c <7% without documented hypoglycemia and without body weight gain

    documented hypoglycemia (defined as ADA Level 1, 2 or 3)

    Time frame: Week 20

  21. Change (mmol/L) in fasting plasma glucose (FPG), 2-hour postprandial glucose (PPG)

    Time frame: from baseline to Week 12 and Week 20

  22. Change (nmol/L) in fasting C-peptide and post-prandial C-peptide

    Time frame: from baseline to Week 12 and Week 20

  23. Change (U and U/Kg) in insulin dose

    Time frame: from baseline to Week 20

  24. Change (kg) in body weight

    Time frame: from baseline to Week 20

  25. Change (%) in TIR [3.9-10.0 mmol/L (70-180 mg/dL)], TAR [>10.0 mmol/L (>180 mg/dL)] and TBR [3.0 mmol/L (<54 mg/dL)] for specific time blocks (6 am-12 pm, 12 pm-6 pm, 6 pm-12 am, and 12 am-6 am)

    Time frame: from baseline to Week 20

  26. Change in diabetes medication treatment satisfaction scores (total score and by subscales), using the treatment-related impact measure diabetes (TRIM-D) questionnaire

    Time frame: from baseline to Week 20

  27. AE, serious adverse event (SAE), and adverse event of special interest (AESI)

    Time frame: from screening to week 21

  28. Overall hypoglycemia events and rates

    Time frame: from screening to week 21

  29. Nocturnal (00:00 h-05:59 h) hypoglycemia events and rates

    Time frame: from baseline to Week 20

  30. Confirmed hypoglycemia (ADA Level 1, 2 and 3)

    * ADA Level 1: Measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L) * ADA Level 2: Measurable glucose concentration \<54 mg/dL (3.0 mmol/L) that needs immediate action * ADA Level 3: Severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery

    Time frame: from baseline to Week 20

07

Study locations

1 of 1 sites recruiting
  • Investigational Site Number: 1560001
    Beijing, 100730, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 21 months after the start.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 21 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 4, 2024
StartActual
Dec 10, 2024
Primary completionEst.
Sep 18, 2026
CompletionEst.
Sep 18, 2026
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06671587
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Dec 10, 2024
Primary completion
Sep 18, 2026 (estimated)
Completion
Sep 18, 2026 (estimated)
Last update
Mar 17, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6
Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion